Balloon Pulmonary Angioplasty (BPA) has revolutionized treatment for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), as discussed in a comprehensive review published on April 14 2025 in the Expert Review of Respiratory Medicine. While Pulmonary Endarterectomy (PEA) continues to be the gold standard for patients with operable disease, many patients cannot undergo this surgical procedure due to distal lesion location, existing health conditions, or persistent hypertension after surgery.
The authors trace Balloon Pulmonary Angioplasty’s development from its early applications to its current widespread adoption globally. Through ongoing refinement of techniques, Balloon Pulmonary Angioplasty has evolved into a safer and more effective intervention. The review not only examines the procedural aspects of Balloon Pulmonary Angioplasty but also explores how complementary medical therapies can enhance overall Chronic Thromboembolic Pulmonary Hypertension management.
Particularly compelling is the inclusion of the authors’ institutional experience, which provides real-world evidence of Balloon Pulmonary Angioplasty’s impact on improving blood flow dynamics and patient survival rates. Despite these advances, they acknowledge that significant challenges remain. The field still lacks standardized protocols for treatment decisions and clearly defined therapeutic goals for optimal outcomes.
Looking forward, the authors emphasize that continued research will be essential to further refine Balloon Pulmonary Angioplasty’s role in the treatment armamentarium and ultimately improve quality of life for patients living with this challenging condition.
Read more at this link on the
Citation
Kuronuma, K., Shimokawahara, H., & Matsubara, H. (2025). An overview of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Expert Review of Respiratory Medicine. https://doi.org/10.1080/17476348.2025.2491721